Tumor sequencing of African ancestry reveals differences in clinically relevant alterations across common cancers
Evelyn Jiagge, Dexter X. Jin, Justin Y. Newberg, Tomin Perea-Chamblee, Kelly R. Pekala, Christopher J. Fong, Michele Waters, Dávid Ma, Yvonne Dei‐Adomakoh, Gilles Erb, Kanika Arora, Sophia L. Maund, Njoki P. Njiraini, Atara Ntekim, Susie Kim, Xuechun Bai, Marlène Thomas, Ronwyn van Eeden, Priti S. Hegde, Justin Jee, Debyani Chakravarty, Nikolaus Schultz, Michael F. Berger, Garrett M. Frampton, Ethan Sokol, Jian Carrot‐Zhang
Abstract
Cancer genomes from patients with African (AFR) ancestry have been poorly studied in clinical research. We leverage two large genomic cohorts to investigate the relationship between genomic alterations and AFR ancestry in six common cancers. Cross-cancer type associations, such as an enrichment of MYC amplification with AFR ancestry in lung, breast, and prostate cancers, and depletion of BRAF alterations are observed in colorectal and pancreatic cancers. There are differences in actionable alterations, such as depletion of KRAS G12C and EGFR L858R, and enrichment of ROS1 fusion with AFR ancestry in lung cancers. Interestingly, in lung cancer, KRAS mutations are less common in both smokers and non-smokers with AFR ancestry, whereas the association of TP53 mutations with AFR ancestry is only seen in smokers, suggesting an ancestry-environment interaction that modifies driver rates. Our study highlights the need to increase representation of patients with AFR ancestry in drug development and biomarker discovery.